Citicoline eye drops 2% not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Glaucoma, Open-Angle
- Main trialPhase 3
- “To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%”In the company’s words, NCT05710198 on ClinicalTrials.gov
Other drugs for Glaucoma, Open-Angle
- Bimatoprost ophthalmic 0.01% YSBPYS Life Science Co., Ltd. · Phase 3
- HUC3-637Huons Co., Ltd. · Phase 3
- Gen 2 Travoprost Intracameral ImplantGlaukos Corporation · Phase 3
- Product DNN.31.19.026Ache Laboratorios Farmaceuticos S.A. · Phase 3
- Bimatoprost 0.01% OphthalmicAmneal Pharmaceuticals, LLC · Phase 3
- DE-117BSanten Pharmaceutical Co., Ltd. · Phase 3
Coming up1
- 1 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 16 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT05710198
- 16 NovCompletion date moved: 2026-04-01 to 2029-07-01 · ClinicalTrials.gov NCT05710198
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Jul 2029 | Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026